Restricted accessResearch articleFirst published online 2014-02
Comparison of Genotypic and Phenotypic HIV Type 1 Tropism Assay: Results from the Screening Samples of Cenicriviroc Study 202,a Randomized Phase II Trial in Treatment-Naive Subjects
Cenicriviroc is a once-daily oral CCR5/CCR2 antagonist in development for treatment of HIV infection. CVC Study 202 (652-2-202; NCT01338883) excluded treatment-naive subjects demonstrated to harbor non-R5 (CXCR4-tropic or dual-mixed) tropic HIV-1 by either genotypic or phenotypic tropism testing. Here we compare the results of genotypic and phenotypic tropism testing in Study 202. A total of 304 subjects screened had paired genotypic and phenotypic results. Genotypic tropism testing (GTT) incorporated triplicate population sequencing using the geno2pheno algorithm and the PSSM algorithm, followed by ultradeep sequencing (UDS) for samples with R5 results. All samples were further evaluated with a phenotypic test, the enhanced-sensitivity Trofile assay (ESTA). Concordance between GTT and ESTA was 80% and increased to 84% when only geno2pheno was used for triplicate population sequencing. GTT (geno2pheno) classified 18% of the samples as non-R5 compared to 16% by ESTA. Only one-third of samples with non-R5 results by either test were classified as non-R5 by both tests. Median CD4(+) cell counts were lower in patients with concordant non-R5 results by UDS and ESTA than in subjects with an R5 result by either assay (p=0.0004). UDS detected non-R5 virus in an additional 27/304 subjects (median 15% non-R5, interquartile range: 3.7–62%) with R5 results by ESTA. In conclusion, the geno2pheno algorithm improves concordance of GTT with a clinically validated phenotypic tropism assay as does the use of UDS. These findings provide support for recent guidelines indicating that genotypic tropism testing may be considered as an alternative to phenotypic testing.
Get full access to this article
View all access options for this article.
References
1.
BergerEA, MurphyPM, and FarberJM: Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol, 1999; 17:657–700.
2.
GoodenowMM and CollmanRG: HIV-1 coreceptor preference is distinct from target cell tropism: A dual-parameter nomenclature to define viral phenotypes. J Leukoc Biol, 2006; 80(5):965–972.
3.
RayN and DomsRW: HIV-1 coreceptors and their inhibitors. Curr Top Microbiol Immunol, 2006; 303:97–120.
4.
ConnorRI, SheridanKE, CeradiniD, ChoeS, and LandauNR: Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med, 1997; 185(4):621–628.
5.
IrlbeckDM, Amrine-MadsenH, KitrinosKM, et al.: Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals. AIDS, 2008; 22(12):1425–1431.
6.
ShankarappaR, MargolickJB, GangeSJ, et al.: Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol, 1999; 73(12):10489–10502.
7.
PovedaE, BrizV, de MendozaC, et al.: Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy. J Med Virol, 2007; 79(8):1040–1046.
8.
BrummeZL, GoodrichJ, MayerHB, et al.: Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis, 2005; 192(3):466–474.
9.
ChalmetK, DauweK, FoquetL, et al.: Presence of CXCR4-using HIV-1 in patients with recently diagnosed infection: Correlates and evidence for transmission. J Infect Dis, 2012; 205(2):174–184.
10.
MoyleGJ, WildfireA, MandaliaS, et al.: Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis, 2005; 191(6):866–872.
11.
DaarES, KeslerKL, PetropoulosCJ, et al.: Baseline HIV type 1 coreceptor tropism predicts disease progression. Clin Infect Dis, 2007; 45(5):643–649.
12.
WeiserB, PhilpottS, KlimkaitT, et al.: HIV-1 coreceptor usage and CXCR4-specific viral load predict clinical disease progression during combination antiretroviral therapy. AIDS, 2008; 22(4):469–479.
13.
DorrP, WestbyM, DobbsS, et al.: Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother, 2005; 49(11):4721–4732.
14.
CooperDA, HeeraJ, GoodrichJ, et al.: Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis, 2010; 201(6):803–813.
15.
FatkenheuerG, NelsonM, LazzarinA, et al.: Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med, 2008; 359(14):1442–1455.
16.
GulickRM, LalezariJ, GoodrichJ, et al.: Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med, 2008; 359(14):1429–1441.
17.
SaagM, GoodrichJ, FatkenheuerG, et al.: A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis, 2009; 199(11):1638–1647.
18.
WhitcombJM, HuangW, FransenS, et al.: Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother, 2007; 51(2):566–575.
19.
GulickRM, SuZ, FlexnerC, et al.: Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-infected, treatment-experienced patients: AIDS clinical trials group 5211. J Infect Dis, 2007; 196(2):304–312.
20.
SuleimanJ, ZingmanBS, DiazRS, et al.: Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial. J Infect Dis, 2010; 201(4):590–599.
21.
WilkinTJ, SuZ, KrambrinkA, et al.: Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatment-experienced patients. J Acquir Immune Defic Syndr, 2010; 54(5):470–476.
22.
ReevesJD, CoakleyE, PetropoulosCJ, and WhitcombJM: An enhanced-sensitivity Trofile™ HIV coreceptor tropism assay for selecting patients for therapy with entry inhibitors targeting CCR5: A review of analytical and clinical studies. J Viral Entry, 2009; 3(3):94–102.
23.
WilkinTJ, GoetzMB, LeducR, et al.: Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity. Clin Infect Dis, 2011; 52(7):925–928.
24.
SuZ, GulickRM, KrambrinkA, et al.: Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: Reanalysis of AIDS clinical trials group A5211. J Infect Dis, 2009; 200(11):1724–1728.
25.
HarriganPR and GerettiAM: Genotypic tropism testing: Evidence-based or leap of faith?. AIDS, 2011; 25(2):257–264.
26.
HwangSS, BoyleTJ, LyerlyHK, and CullenBR: Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science, 1991; 253(5015):71–74.
27.
McGovernRA, ThielenA, MoT, et al.: Population-based V3 genotypic tropism assay: A retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS, 2010; 24(16):2517–2525.
28.
McGovernRA, ThielenA, PortsmouthS, et al.: Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial. J Acquir Immune Defic Syndr, 2012; 61(3):279–286.
29.
ProsperiMC, BraccialeL, FabbianiM, et al.: Comparative determination of HIV-1 co-receptor tropism by enhanced sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping. Retrovirology, 2010; 7:56.
30.
Recordon-PinsonP, SoulieC, FlandreP, et al.: Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: The ANRS GenoTropism study. Antimicrob Agents Chemother, 2010; 54(8):3335–3340.
31.
SymonsJ, VandekerckhoveL, ParedesR, et al.: Impact of triplicate testing on HIV genotypic tropism prediction in routine clinical practice. Clin Microbiol Infect, 2012; 18(6):606–612.
32.
KnappDJ, McGovernRA, DongW, et al.: Factors influencing the sensitivity and specificity of conventional sequencing in human immunodeficiency virus type 1 tropism testing. J Clin Microbiol, 2013; 51(2):444–451.
33.
MarguliesM, EgholmM, AltmanWE, et al.: Genome sequencing in microfabricated high-density picolitre reactors. Nature, 2005; 437(7057):376–380.
34.
ArcherJ, BravermanMS, TaillonBE, et al.: Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing. AIDS, 2009; 23(10):1209–1218.
35.
DaumerM, KaiserR, KleinR, LengauerT, ThieleB, and ThielenA: Genotypic tropism testing by massively parallel sequencing: Qualitative and quantitative analysis. BMC Med Inform Decis Mak, 2011; 11:30.
36.
SwensonLC, MooresA, LowAJ, et al.: Improved detection of CXCR4-using HIV by V3 genotyping: Application of population-based and “deep” sequencing to plasma RNA and proviral DNA. J Acquir Immune Defic Syndr, 2010; 54(5):506–510.
37.
WangC, MitsuyaY, GharizadehB, RonaghiM, and ShaferRW: Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res, 2007; 17(8):1195–1201.
38.
KaganRM, JohnsonEP, SiawM, et al.: A genotypic test for HIV-1 tropism combining Sanger sequencing with ultradeep sequencing predicts virologic response in treatment-experienced patients. PLoS One, 2012; 7(9):e46334.
39.
SwensonLC, MoT, DongWW, et al.: Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. J Infect Dis, 2011; 203(2):237–245.
40.
SwensonLC, MoT, DongWW, et al.: Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: A reanalysis of the MERIT trial of maraviroc. Clin Infect Dis, 2011; 53(7):732–742.
41.
KlibanovOM, WilliamsSH, and IlerCA: Cenicriviroc, an orally active CCR5 antagonist for the potential treatment of HIV infection. Curr Opin Investig Drugs, 2010; 11(8):940–950.
42.
LalezariJ, GatheJ, BrinsonC, et al.: Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subjects. J Acquir Immune Defic Syndr, 2011; 57(2):118–125.
43.
MarierJF, TrinhM, PhengLH, PallejaSM, and MartinDE: Pharmacokinetics and pharmacodynamics of TBR-652, a novel CCR5 antagonist, in HIV-1-infected, antiretroviral treatment-experienced, CCR5 antagonist-naive patients. Antimicrob Agents Chemother, 2011; 55(6):2768–2774.
44.
McGovernRA, HarriganPR, and SwensonLC: Genotypic inference of HIV-1 tropism using population-based sequencing of V3. J Visual Exp: JoVE, 2010(46).
45.
WoodsCK, BrummeCJ, LiuTF, et al.: Automating HIV drug resistance genotyping with RECall, a freely accessible sequence analysis tool. J Clin Microbiol, 2012; 50(6):1936–1942.
46.
SingT, LowAJ, BeerenwinkelN, et al.: Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther, 2007; 12(7):1097–1106.
47.
JensenMA, LiFS, van 't WoutAB, et al.: Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol, 2003; 77(24):13376–13388.
48.
VandekerckhoveLP, WensingAM, KaiserR, et al.: European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis, 2011; 11(5):394–407.
49.
SeclenE, SorianoV, GonzalezMM, GomezS, ThielenA, and PovedaE: High concordance between the position-specific scoring matrix and geno2pheno algorithms for genotypic interpretation of HIV-1 tropism: V3 length as the major cause of disagreement. J Clin Microbiol, 2011; 49(9):3380–3382.
50.
RaymondS, Recordon-PinsonP, SaliouA, et al.: Improved V3 genotyping with duplicate PCR amplification for determining HIV-1 tropism. J Antimicrob Chemother, 2011; 66(9):1972–1975.
51.
PortsmouthS, ValluriSR, DaumerM, et al.: Correlation between genotypic (V3 population sequencing) and phenotypic (Trofile ES) methods of characterizing co-receptor usage of HIV-1 from 200 treatment-naive HIV patients screened for Study A4001078. Antiviral Res, 2013; 97(1):60–65.
52.
BuonaguroL, TorneselloML, and BuonaguroFM: Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: Pathogenetic and therapeutic implications. J Virol, 2007; 81(19):10209–10219.
53.
RaymondS, DelobelP, MavignerM, et al.: Prediction of HIV type 1 subtype C tropism by genotypic algorithms built from subtype B viruses. J Acquir Immune Defic Syndr, 2010; 53(2):167–175.
54.
LeeGQ, HarriganPR, DongW, et al.: Comparison of population and 454 “deep” sequence analysis for HIV-1 tropism versus the original Trofile assay in non-B subtypes. AIDS Res Hum Retroviruses, 2013; 29(6):979–984.
55.
RaymondS, DelobelP, ChaixML, et al.: Genotypic prediction of HIV-1 subtype D tropism. Retrovirology, 2011; 8:56.
56.
RaymondS, DelobelP, MavignerM, et al.: Genotypic prediction of human immunodeficiency virus type 1 CRF02-AG tropism. J Clin Microbiol, 2009; 47(7):2292–2294.
57.
Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed February12, 2013.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
